News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Articles by Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Standard of Care for BRCA+ mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Testing for PD-L1 Expression in mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

KEYNOTE-355 Trial in mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Standard of Care for Metastatic TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Current Trials for Treatment of Early Stage TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Emerging Data on Biomarkers in ES TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

ICI-Based Therapy in TNBC: Immune-Related Adverse Events

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Early Stage TNBC: Phase 3 IMpassion031 Study

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Key Trials in ICI-Based Therapy for Early Stage TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Role of pCR in Early Stage TNBC Management

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Standard of Care for Early-Stage TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Q&A: Practical Considerations in HER2+ Breast Cancer

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

The Impact of Subcutaneous Option for HER2+ BC

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

Administration of Dual HER2-Targeted Therapy in BC

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

Dual HER2-Targeted Approaches in Breast Cancer

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

Historic Perspectives on HER2+ Breast Cancer

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies